Cargando…
A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma
Patients with advanced intrahepatic cholangiocarcinoma (ICC) have a poor prognosis and the therapeutic options available for treating ICC are limited. Sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet derived growth factor receptor-β, B-Raf proto-onc...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431743/ https://www.ncbi.nlm.nih.gov/pubmed/28529557 http://dx.doi.org/10.3892/ol.2017.5847 |